| Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... The Lancet 398 (10295), 131-142, 2021 | 205 | 2021 |
| Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) O Arrieta, AF Cardona, C Martín, L Más-López, L Corrales-Rodríguez, ... Journal of Thoracic Oncology 10 (5), 838-843, 2015 | 203 | 2015 |
| Lung cancer in never smokers: The role of different risk factors other than tobacco smoking L Corrales, R Rosell, AF Cardona, C Martin, ZL Zatarain-Barron, O Arrieta Critical reviews in oncology/hematology 148, 102895, 2020 | 185 | 2020 |
| Immunotherapy comes of age in lung cancer P Khanna, N Blais, PO Gaudreau, L Corrales-Rodriguez Clinical lung cancer 18 (1), 13-22, 2017 | 101 | 2017 |
| The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer O Arrieta, AF Cardona, L Corrales, AD Campos-Parra, R Sánchez-Reyes, ... Lung cancer 87 (2), 169-175, 2015 | 98 | 2015 |
| Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations J Carrot-Zhang, G Soca-Chafre, N Patterson, AR Thorner, A Nag, ... Cancer discovery 11 (3), 591-598, 2021 | 93 | 2021 |
| Lung cancer associated venous thromboembolic disease: a comprehensive review L Corrales-Rodriguez, N Blais Lung cancer 75 (1), 1-8, 2012 | 77 | 2012 |
| Immunotherapy in lung cancer: a new age in cancer treatment L Corrales, K Scilla, C Caglevic, K Miller, J Oliveira, C Rolfo Immunotherapy, 65-95, 2018 | 66 | 2018 |
| Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study L Corrales-Rodriguez, D Soulières, X Weng, M Tehfe, M Florescu, N Blais Thrombosis Research 133 (1), 48-51, 2014 | 59 | 2014 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label … S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee, AC Yopp, J Zhou, ... The Lancet 402 (10415), 1835-1847, 2023 | 53 | 2023 |
| EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1. 2-CLICaP) AF Cardona, L Rojas, ZL Zatarain-Barrón, HC Freitas, ST Granados, ... Lung Cancer 125, 265-272, 2018 | 52 | 2018 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial SY Rha, DY Oh, P Yañez, Y Bai, MH Ryu, J Lee, F Rivera, GV Alves, ... The Lancet Oncology 24 (11), 1181-1195, 2023 | 48 | 2023 |
| Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) A Ruiz‐Patiño, O Arrieta, AF Cardona, C Martín, LE Raez, ... Thoracic Cancer 11 (2), 353-361, 2020 | 44 | 2020 |
| LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) JS De Bono, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... Annals of Oncology 31, S1153-S1154, 2020 | 40 | 2020 |
| Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials A Ramos-Esquivel, A van der Laat, R Rojas-Vigott, M Juárez, ... ESMO open 2 (3), e000236, 2017 | 40 | 2017 |
| An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP) L Corrales-Rodríguez, O Arrieta, L Mas, R Báez-Saldaña, ... Lung Cancer 113, 30-36, 2017 | 31 | 2017 |
| Molecular epidemiology of ALK rearrangements in advanced lung adenocarcinoma in Latin America O Arrieta, AF Cardona, G Bramuglia, G Cruz-Rico, L Corrales, C Martín, ... Oncology 96 (4), 207-216, 2019 | 30 | 2019 |
| BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations AF Cardona, L Rojas, B Wills, O Arrieta, H Carranza, C Vargas, J Otero, ... Oncotarget 7 (42), 68933, 2016 | 30 | 2016 |
| EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP) A Ruiz-Patiño, CD Castro, LM Ricaurte, AF Cardona, L Rojas, ... Targeted oncology 13, 621-629, 2018 | 29 | 2018 |
| The armed conflict and the impact on patients with cancer in Ukraine: Urgent considerations C Caglevic, C Rolfo, I Gil-Bazo, A Cardona, J Sapunar, FR Hirsch, ... JCO Global Oncology 8, e2200123, 2022 | 25 | 2022 |
Oscar ArrietaHead of the Thoracic Oncology Unit, Instituto Nacional de Cancerología de MexicoVerified email at unam.mx
